In QQ4 2024, Innovative MedTech Inc (IMTH) posted revenue of 456,361 and a gross profit of 441,901, yielding a very high gross margin of 96.83%. Despite top-line performance, the company incurred a substantial operating loss driven by elevated SG&A and operating expenses totaling 3,525,000, producing an operating income of -3,069,000 and an EBITDA of -6,602,000. Net income for the quarter was -6,676,000 with an EPS of -0.28. YoY revenue rose 2.96% and QoQ revenue rose 0.26%, but profitability deteriorated meaningfully as fixed cost absorption remained high relative to revenue, and other income/expense items compounded the loss. The quarterly cash flow framework showed operating cash flow of -36,069, with capital expenditures of 44,559, contributing to a reported free cash flow figure of 8,490 and a net cash increase of 9,209 for the period. Cash at end of period stood at 113,489. From a balance sheet perspective, total assets were reported at 651,881, while total liabilities were 6,134,843, yielding a negative stockholders’ equity of -5,482,962. Net debt was approximately 2.08 million, with liquidity metrics showing a current ratio and quick ratio near 0.07, signaling materially stressed near-term liquidity. Data inconsistencies across line items (e.g., assets vs. liabilities) warrant caution when interpreting the balance sheet. Without explicit forward guidance, the near-term trajectory hinges on controlling overhead, improving revenue visibility, and addressing leverage. Investors should monitor cash burn dynamics, potential debt restructurings, and any strategic actions to stabilize earnings power.